These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1173788)

  • 41. Relationships among immunoglobulin markers in Graves' disease.
    Ozawa Y; Maciel RM; Chopra IJ; Solomon DH; Beall GN
    J Clin Endocrinol Metab; 1979 Mar; 48(3):381-7. PubMed ID: 581874
    [No Abstract]   [Full Text] [Related]  

  • 42. [TSH and the "long-acting thyroid stimulator" (LATS) in patients with compensated hyperthyroidism].
    zur Mühlen A von ; Hesch RD; von Lilienfeld H; Emrich D
    Acta Endocrinol Suppl (Copenh); 1971; 152():86. PubMed ID: 5313711
    [No Abstract]   [Full Text] [Related]  

  • 43. [Incidence of L.A.T.S. demonstration in untreated recent hyperthyroidism. Comparison of 2 continuous series].
    Mornex R; Massin JP; Orgiazzi J; Savoie JC
    Ann Endocrinol (Paris); 1972; 33(2):177-84. PubMed ID: 4678455
    [No Abstract]   [Full Text] [Related]  

  • 44. Placental transmission of thyroid-stimulating immunoglobulins.
    Dirmikis SM; Munro DS
    Br Med J; 1975 Jun; 2(5972):665-6. PubMed ID: 1173561
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of iodine administration on the thyrotropic hormone and long-acting thyroid stimulator level in the plasma].
    Földes J; Krasznai I; Piroska E; Gesztesi E; Takács I
    Endokrinologie; 1967; 52(1):80-7. PubMed ID: 4171706
    [No Abstract]   [Full Text] [Related]  

  • 46. [Characterization of the long-acting thyroid stimulator. Considerations on preliminary results].
    Tourneur R; Letonturier P; Sénécal P
    MMW Munch Med Wochenschr; 1974 Mar; 116(13):677-9. PubMed ID: 4212576
    [No Abstract]   [Full Text] [Related]  

  • 47. [Fluctuations of the long-acting thyroid stimulator (LATS) concentration in the blood and its significance in hyperthyroidism].
    Noguchi A; Kurihara H; Ozeki Y; Sato S
    Nihon Rinsho; 1967 Oct; 25(8):1723-32. PubMed ID: 5626106
    [No Abstract]   [Full Text] [Related]  

  • 48. [Hyperthyroidism and the "long acting thyroid stimulator" (LATS)].
    Studer H
    Schweiz Med Wochenschr; 1967 May; 97(19):622-3. PubMed ID: 5632362
    [No Abstract]   [Full Text] [Related]  

  • 49. Thyroid-stimulating autoantibodies.
    Adams DD
    Vitam Horm; 1980; 38():119-203. PubMed ID: 6291240
    [No Abstract]   [Full Text] [Related]  

  • 50. [LATS production by lymphocyte culture].
    Fukuchi M
    Nihon Naibunpi Gakkai Zasshi; 1969 Oct; 45(7):766-77. PubMed ID: 5394607
    [No Abstract]   [Full Text] [Related]  

  • 51. [Determination of serum TSH (including analyses of long-acting thyroid stimulator and thyroid stimulating immunoglobulins)].
    Mori T; Kasagi K; Endo K; Ikekubo K; Konishi J
    Nihon Rinsho; 1976; 34 suppl():2212-23. PubMed ID: 792508
    [No Abstract]   [Full Text] [Related]  

  • 52. A prospective study of the effects of radio-iodine therapy on thyroid-stimulating antibody synthesis in Grave's disease [proceedings].
    McGregor AM; Petersen MM; Capifferi R; Evered DC; Smith BR; Hall R
    J Endocrinol; 1979 May; 81(2):114P-115P. PubMed ID: 222864
    [No Abstract]   [Full Text] [Related]  

  • 53. Thyrotoxicosis and Graves disease.
    Safran M; Braverman LE
    Hosp Pract (Off Ed); 1985 Mar; 20(3A):33-42, 46-9. PubMed ID: 3932411
    [No Abstract]   [Full Text] [Related]  

  • 54. Concentration of long-acting thyroid stimulator (LATS) by subfractionation of gamma G globulin from Graves' disease serum.
    Miyai K; Werner SC
    J Clin Endocrinol Metab; 1966 May; 26(5):504-12. PubMed ID: 5952570
    [No Abstract]   [Full Text] [Related]  

  • 55. Studies on the pathogenesis of the ophthalmopathy of Graves' disease.
    Kriss JP; Pleshakov V; Rosenblum AL; Holderness M; Sharp G; Utiger R
    J Clin Endocrinol Metab; 1967 Apr; 27(4):582-93. PubMed ID: 6071430
    [No Abstract]   [Full Text] [Related]  

  • 56. [Pitfalls in the biological demonstration of the "long acting thyroid stimulator" (LATS)].
    Mertz DP; Stelzer M
    Schweiz Med Wochenschr; 1968 Sep; 98(38):1471-5. PubMed ID: 5680881
    [No Abstract]   [Full Text] [Related]  

  • 57. LATS protector and abnormal thyroid stimulation in diffuse toxic goitre.
    Stewart RD
    N Z Med J; 1975 Jan; 81(531):24. PubMed ID: 1055311
    [No Abstract]   [Full Text] [Related]  

  • 58. Plasma thyrotropin (TSH) and long-acting thyroid stimulator (LATS) in patients treated for thyroid carcinoma.
    Valenta L; Lemarchand-Béraud T; Vannotti A
    Eur J Cancer (1965); 1970 Apr; 6(2):139-43. PubMed ID: 5450187
    [No Abstract]   [Full Text] [Related]  

  • 59. Long-acting thyroid stimulator protector assay as a basis for identification of subgroups of Graves' ophthalmopathy.
    Solomon DH; Chopra IJ; Chopra U; Smith F
    Trans Assoc Am Physicians; 1976; 89():159-70. PubMed ID: 828344
    [No Abstract]   [Full Text] [Related]  

  • 60. Role of thyrotropin receptor antibodies in the development of hyperthyroidism: follow-up studies on nine patients with Graves' disease.
    Kasagi K; Tamai H; Morita T; Hidaka A; Hatabu H; Misaki T; Iida Y; Ishihara T; Ikekubo K; Kuma K
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1189-94. PubMed ID: 2566620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.